Microchips moves osteoporosis device into clinical study

Thu, 02/03/2011 - 9:38am
Mass High Tech: The Journal of New England Technology

Some 18 years after MIT professor Robert Langer first envisioned using an implantable reservoir as a drug delivery device, one of his companies, MicroCHIPS Inc. of Bedford, announced today that it is initiating a clinical study of a device that delivers a peptide over the course of months in women with osteoporosis.

The study, now being conducted in Denmark, will focus on controlled delivery of a parathyroid hormone, (PTH (1-34), from a programmable, multi-reservoir implanted system over the course of months without need for daily injections. The goal is to increase bone density in women suffering from severe osteoporosis.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.